234 related articles for article (PubMed ID: 19864234)
1. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.
Harrington AM; Hari P; Kroft SH
Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
4. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
6. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
7. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
9. Instability of immunophenotype in plasma cell myeloma.
Cao W; Goolsby CL; Nelson BP; Singhal S; Mehta J; Peterson LC
Am J Clin Pathol; 2008 Jun; 129(6):926-33. PubMed ID: 18480010
[TBL] [Abstract][Full Text] [Related]
10. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?
Tatsas AD; Jagasia MH; Chen H; McCurley TL
Am J Clin Pathol; 2010 Jul; 134(1):139-44. PubMed ID: 20551278
[TBL] [Abstract][Full Text] [Related]
11. The immunophenotypic stability of plasma cell myeloma by flow cytometry.
Spears MD; Olteanu H; Kroft SH; Harrington AM
Int J Lab Hematol; 2011 Oct; 33(5):483-91. PubMed ID: 21470371
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
Joshi R; Horncastle D; Elderfield K; Lampert I; Rahemtulla A; Naresh KN
J Clin Pathol; 2008 Feb; 61(2):213-6. PubMed ID: 17526802
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases.
Swan N; Skinner M; O'Hara CJ
Am J Clin Pathol; 2003 Oct; 120(4):610-6. PubMed ID: 14560572
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma with flow cytometric evidence of clonal plasmacytic differentiation: a case report.
Naushad H; Choi WW; Page CJ; Sanger WG; Weisenburger DD; Aoun P
Cytometry B Clin Cytom; 2009 May; 76(3):218-24. PubMed ID: 19061249
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
[TBL] [Abstract][Full Text] [Related]
17. Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry.
Ash S; Luria D; Cohen IJ; Goshen Y; Toledano H; Issakov J; Yaniv I; Avigad S
Clin Cancer Res; 2011 May; 17(9):2900-7. PubMed ID: 21467162
[TBL] [Abstract][Full Text] [Related]
18. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
19. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system.
Chang H; Bartlett ES; Patterson B; Chen CI; Yi QL
Br J Haematol; 2005 May; 129(4):539-41. PubMed ID: 15877737
[TBL] [Abstract][Full Text] [Related]
20. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
